DANA MILLIGAN: Open Payments
NPI 1235565367 · HARTFORD, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 39 payments from 14 companies in 2025. Trend: 2023 $218 · 2024 $456 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $225 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $74 |
| PFIZER INC. | 4 | $60 |
| ACADIA Pharmaceuticals Inc | 1 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Corcept Therapeutics | 2 | $40 |
| Amgen Inc. | 2 | $39 |
| Novo Nordisk Inc | 2 | $37 |
| Lundbeck LLC | 2 | $36 |
Products named: VRAYLAR, CAPLYTA, UBRELVY, NUPLAZID, REXULTI, VOQUEZNA, QULIPTA, NURTEC ODT.
Industry payments across KY — which companies pay providers there.
